September 25, 2024
TOPLINE: Treatment-resistant major depression (TRD) is associated with a 17% higher risk for all-cause mortality than non-TRD major depressive disorder (MDD), a new study shows. The […]
September 25, 2024
TOPLINE: Menopausal hormone therapy (MHT) is associated with a 16% lower risk for psychosis relapse in women with schizophrenia or schizoaffective disorder (SSD), especially in women […]
September 24, 2024
MILAN — Recent research allaying concerns about suicidality linked to glucagon-like peptide 1 (GLP-1) receptor agonists, along with evidence of these agents’ potential psychiatric and cognitive […]
September 24, 2024
Loneliness is widely recognized as a health risk factor, linked to conditions like cardiovascular disease, psychiatric disorders, and increased risks for stroke and dementia. However, new […]
September 23, 2024
MILAN — Psilocybin leads to a better overall outcome in the treatment of moderate to severe major depressive disorder (MDD) than the selective serotonin reuptake inhibitor […]
September 20, 2024
The US Food and Drug Administration (FDA) is due to issue a decision by September 26 on the approval of KarXT, a potential first-in-class antipsychotic. If […]
September 17, 2024
TOPLINE: Antipsychotic use for schizophrenia or other psychotic disorders is associated with increased risk for severe COVID-19 or other respiratory infection and related hospitalization, a new […]
September 13, 2024
US suicide rates have reached alarming levels, with data from Centers for Disease Control and Prevention (CDC) showing a 37% increase from 2000 to 2022. Nearly […]
September 13, 2024
TOPLINE: In 2022, nearly 22% of people who died of drug overdose had a non–substance-related mental health disorder (MHD), new data from the US Centers for […]